American Well (NYSE:AMWL) Insider Dmitry Zamansky Sells 5,575 Shares of Stock

American Well Corporation (NYSE:AMWL) insider Dmitry Zamansky sold 5,575 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $5.30, for a total transaction of $29,547.50. Following the sale, the insider owned 241,080 shares of the company’s stock, valued at approximately $1,277,724. This represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Dmitry Zamansky also recently made the following trade(s):

• On Friday, January 2nd, Dmitry Zamansky sold 6,243 shares of American Well stock. The stock was sold at an average price of $4.85, for a total transaction of $30,278.55.

American Well Trading Up 4.1%

Shares of NYSE:AMWL opened at $5.51 on Friday. The firm has a market cap of $91.11 million, a price-to-earnings ratio of -0.93 and a beta of 1.39. American Well Corporation has a 1 year low of $3.71 and a 1 year high of $9.15. The business has a fifty day simple moving average of $5.22 and a 200 day simple moving average of $5.09.

American Well (NYSE:AMWL) last issued its earnings results on Thursday, February 12th. The company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.07. American Well had a negative return on equity of 35.33% and a negative net margin of 38.38%.The firm had revenue of $55.31 million for the quarter, compared to the consensus estimate of $52.71 million. On average, sell-side analysts forecast that American Well Corporation will post -9.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Stifel Nicolaus cut their price objective on shares of American Well from $6.00 to $5.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. Morgan Stanley dropped their price target on shares of American Well from $10.50 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Wall Street Zen upgraded shares of American Well from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.42.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in American Well by 280.6% during the first quarter. Goldman Sachs Group Inc. now owns 64,760 shares of the company’s stock valued at $510,000 after acquiring an additional 47,745 shares during the period. Jane Street Group LLC lifted its position in shares of American Well by 232.9% during the 1st quarter. Jane Street Group LLC now owns 64,112 shares of the company’s stock worth $505,000 after purchasing an additional 44,852 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of American Well by 16.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock worth $131,000 after purchasing an additional 2,081 shares during the last quarter. Norges Bank bought a new stake in American Well during the 2nd quarter valued at approximately $250,000. Finally, Engineers Gate Manager LP acquired a new stake in American Well in the 2nd quarter valued at approximately $101,000. Institutional investors own 56.05% of the company’s stock.

About American Well

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.